Alnylam Pharmaceuticals Inc. Hits New 52-Week High at $112.57 (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) set a new 52-week high during trading hours on Monday, Analyst Ratings Net reports. The company traded as high as $112.57 and last traded at $91.51, with a volume of 4,584,148 shares. The stock had previously closed at $66.21.
Several analysts have recently commented on the stock. Analysts at S&P Equity Research downgraded shares of Alnylam Pharmaceuticals to a “neutral” rating in a research note to investors on Monday. Separately, analysts at JMP Securities reiterated a “market perform” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note to investors on Thursday. They now have a $67.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $63.43.
Alnylam Pharmaceuticals has a 52 week low of $19.23 and a 52 week high of $67.97. The stock’s 50-day moving average is $62.47 and its 200-day moving average is $54.49. The company’s market cap is $5.928 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings data on Wednesday, November 6th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.39) by $0.09. The company had revenue of $9.00 million for the quarter, compared to the consensus estimate of $8.64 million. During the same quarter last year, the company posted ($0.31) earnings per share. Alnylam Pharmaceuticals’s revenue was down 46.4% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post $-1.38 EPS for the current fiscal year.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.